Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of CS1003 + lenvatinib versus placebo + lenvatinib as first-line treatment for advanced hepatocellular carcinoma
CTR20192524Phase 3Active
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of nofazinlimab in hepatocellular carcinoma (HCC), sponsored by Cornerstone Pharmaceuticals. Started Dec 2019; status: active.
02
Drugs
nofazinlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20192524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192524.